Five Prime down on disappointing cabiralizumab combo data

Five Prime Therapeutics Inc. (NASDAQ:FPRX) plummeted $17.90 (41%) to $25.86 on Tuesday following a preliminary Phase Ia data readout for cabiralizumab (FPA008) in combination with Opdivo nivolumab to treat advanced solid tumors. The data were reported in an abstract released ahead of the Society for Immunotherapy of Cancer meeting in National Harbor, Md.

Among 31 evaluable pancreatic cancer patients who were previously treated with chemotherapy or were naïve to immunotherapy, cabiralizumab plus Opdivo led to an objective response rate (ORR) of 10%, including three confirmed partial responses, and a six-month disease control rate (DCR) of 13%. Among the trial's 205 patients with advanced solid tumors, the combination led to grade three to five cabiralizumab-related adverse events in 43% of patients, with a discontinuation rate due to adverse events of 13%...